Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.

Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A.

Cancer Cytopathol. 2010 Oct 25;118(5):287-97. doi: 10.1002/cncy.20095.

2.

Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.

Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, Loeschke S, Bullerdiek J.

Genes Chromosomes Cancer. 2008 Jan;47(1):56-63.

PMID:
17943974
3.

Human telomerase reverse transcriptase expression in Diff-Quik-stained FNA samples from thyroid nodules.

Siddiqui MT, Greene KL, Clark DP, Xydas S, Udelsman R, Smallridge RC, Zeiger MA, Saji M.

Diagn Mol Pathol. 2001 Jun;10(2):123-9.

PMID:
11385322
4.

Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms.

Liou MJ, Chan EC, Lin JD, Liu FH, Chao TC.

Cancer Lett. 2003 Mar 10;191(2):223-7.

PMID:
12618337
5.

HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR.

Jin L, Lloyd RV, Nassar A, Lappinga PJ, Sebo TJ, Swartz K, Seys AR, Erickson-Johnson MR, Roth CW, Evers BR, Oliveira AM, Zhang J.

Diagn Mol Pathol. 2011 Jun;20(2):71-80. doi: 10.1097/PDM.0b013e3181ed784d.

PMID:
21532495
6.

Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?

Letsas KP, Vartholomatos G, Tsepi C, Tsatsoulis A, Frangou-Lazaridis M.

Neoplasma. 2007;54(1):57-62.

PMID:
17203893
7.

Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.

Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR.

N Engl J Med. 2012 Aug 23;367(8):705-15. doi: 10.1056/NEJMoa1203208. Epub 2012 Jun 25.

8.

Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors.

Umbricht CB, Conrad GT, Clark DP, Westra WH, Smith DC, Zahurak M, Saji M, Smallridge RC, Goodman S, Zeiger MA.

Clin Cancer Res. 2004 Sep 1;10(17):5762-8.

10.

Clinical outcomes for "suspicious" category in thyroid fine-needle aspiration biopsy: Patient's sex and nodule size are possible predictors of malignancy.

Raparia K, Min SK, Mody DR, Anton R, Amrikachi M.

Arch Pathol Lab Med. 2009 May;133(5):787-90. doi: 10.1043/1543-2165-133.5.787.

PMID:
19415954
11.

A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.

Keutgen XM, Filicori F, Crowley MJ, Wang Y, Scognamiglio T, Hoda R, Buitrago D, Cooper D, Zeiger MA, Zarnegar R, Elemento O, Fahey TJ 3rd.

Clin Cancer Res. 2012 Apr 1;18(7):2032-8. doi: 10.1158/1078-0432.CCR-11-2487. Epub 2012 Feb 20.

12.

Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?

Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW.

Diagn Cytopathol. 2006 May;34(5):330-4.

13.

Clinical significance of distinguishing between follicular lesion and follicular neoplasm in thyroid fine-needle aspiration biopsy.

Williams MD, Suliburk JW, Staerkel GA, Busaidy NL, Clayman GL, Evans DB, Perrier ND.

Ann Surg Oncol. 2009 Nov;16(11):3146-53. doi: 10.1245/s10434-009-0666-3.

PMID:
19727961
14.

Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations.

Yang J, Schnadig V, Logrono R, Wasserman PG.

Cancer. 2007 Oct 25;111(5):306-15.

15.

Genetic markers differentiating follicular thyroid carcinoma from benign lesions.

Freitas BC, Cerutti JM.

Mol Cell Endocrinol. 2010 May 28;321(1):77-85. doi: 10.1016/j.mce.2009.11.008. Epub 2009 Nov 20. Review.

PMID:
19932149
16.

Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.

Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A.

Surgery. 2005 Dec;138(6):1102-9; discussion 1109-10.

PMID:
16360397
17.

Cytology and mRNA expression analysis of fine needle aspirates of thyroid nodules in an East German region with borderline iodine deficiency.

Karger S, Engelhardt C, Eszlinger M, Tönjes A, Herrmann F, Müller P, Schmidt T, Weiss CL, Dralle H, Lippitzsch F, Tannapfel A, Führer D.

Horm Metab Res. 2006 Oct;38(10):662-7.

PMID:
17075775
18.

Telomerase activity in "suspicious" thyroid cytology.

Lerma E, Mora J.

Cancer. 2005 Dec 25;105(6):492-7.

19.

Utility of fine-needle aspiration cytology and frozen-section examination in the operative management of thyroid nodules.

Davoudi MM, Yeh KA, Wei JP.

Am Surg. 1997 Dec;63(12):1084-9; discussion 1089-90.

PMID:
9393257
20.

A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression.

Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK.

Surgery. 2005 Dec;138(6):1050-6; discussion 1056-7.

PMID:
16360390

Supplemental Content

Support Center